Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
March 29, 2019 Off

CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study

By BusinessWire

VIENNA, Va.–(BUSINESS WIRE)–CEL-SCI Corporation (NYSE American: CVM) announced today that the Independent Data Monitoring Committee (IDMC) for the Company’s pivotal…

Millendo Reports Full Year 2018 Operating and Financial Results
March 29, 2019 Off

Millendo Reports Full Year 2018 Operating and Financial Results

By BusinessWire

–Initiated ZEPHYR, a pivotal Phase 2b/3 clinical study of livoletide for patients with Prader-Willi syndrome (PWS), in 1Q19– –Topline data…

March 29, 2019 Off

Global Rheumatoid Arthritis Drugs Market Outlook to 2024 – Non-steroidal Anti-inflammatory Drugs (NSAIDs) Projected to Dominate – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Rheumatoid Arthritis Drugs Market- Growth, Trends, and Forecast (2019 – 2024)” report has been added to ResearchAndMarkets.com’s offering.…

March 29, 2019 Off

Global Preventive Vaccines Market Growth, Trends and Forecasts (2019-2024): AstraZeneca, Emergent BioSolutions, Daiichi Sankyo Co, GlaxoSmithKline, and Johnson & Johnson are Dominating – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Global Preventive Vaccines Market – Growth, Trends, and Forecast (2019 – 2024)” report has been added to ResearchAndMarkets.com’s…

March 29, 2019 Off

Tilray® Expands Manufacturing Capacity with New Processing License from Health Canada

By BusinessWire

Newly-acquired Natura Naturals Inc. located in Leamington, Ontario obtains processing license, allowing it to produce a wide range of cannabis…

March 29, 2019 Off

Seattle Genetics Completes Enrollment in Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer

By BusinessWire

-Phase 2 innovaTV 204 Trial Designed to Support Potential Accelerated Approval Pathway in U.S.- BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq:SGEN)…

March 29, 2019 Off

Bicycle Therapeutics to Present Preclinical Data on EphA2 and Nectin-4 Bicycle Toxin Conjugate Programs, as well as a CD137 Immune Oncology Program, at the American Association for Cancer Research Annual Meeting

By BusinessWire

CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic…

March 29, 2019 Off

Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids, 2019-2030 Markets – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids, 2019-2030” report has been added to ResearchAndMarkets.com’s offering.…

March 29, 2019 Off

bluebird bio Receives Positive Opinion from CHMP for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia (TDT) Who Do Not Have β0/β0 Genotype

By BusinessWire

First gene therapy recommended for approval in the EU for TDT Treatment with ZYNTEGLO has been shown to help eliminate…

March 29, 2019 Off

Antibe Therapeutics Announces Commencement of Phase 2B Dose-Ranging, Efficacy Study for Lead Drug, ATB-346

By BusinessWire

TORONTO–(BUSINESS WIRE)–Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation,…

Posts pagination

Previous 1 … 3,320 3,321 3,322 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine